Kodiak Sciences Inc (KOD)

Currency in USD
8.840
+0.590(+7.15%)
Closed·
After Hours
8.690-0.150(-1.70%)
·
KOD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
7.9608.860
52 wk Range
1.92011.600
Key Statistics
Prev. Close
8.25
Open
8.27
Day's Range
7.96-8.86
52 wk Range
1.92-11.6
Volume
920.15K
Average Volume (3m)
428.19K
1-Year Change
174.53%
Book Value / Share
2.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KOD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.250
Downside
-17.99%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Kodiak Sciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Kodiak Sciences Inc Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc SWOT Analysis


Pipeline Promise
Explore Kodiaq Sciences' diverse eye disease treatment portfolio, including KSI-101, tarcocimab, and KSI-501, with key trial results expected in 2025-2026
Financial Hurdles
Delve into the company's financial challenges, with negative EPS forecasts and a declining stock price, balanced against its cash-rich balance sheet
Market Positioning
Learn how Kodiaq Sciences aims to differentiate itself in the competitive biotech sector through innovative treatments and a new wearable OCT device
Future Outlook
Analyst price targets range from $3 to $4, reflecting cautious optimism amid clinical trial uncertainties and potential market opportunities
Read full SWOT analysis

Compare KOD to Peers and Sector

Metrics to compare
KOD
Peers
Sector
Relationship
P/E Ratio
−2.4x−1.9x−0.5x
PEG Ratio
−0.13−0.040.00
Price/Book
4.3x0.9x2.6x
Price / LTM Sales
-81.9x3.2x
Upside (Analyst Target)
−58.3%264.5%41.7%
Fair Value Upside
Unlock14.9%6.1%Unlock

Analyst Ratings

2 Buy
1 Hold
3 Sell
Ratings:
6 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 7.250
(-17.99% Downside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
1.09 / -1.05
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

KOD Income Statement

People Also Watch

447.49
MEDP
-1.80%
11.93
SRPT
-7.38%
25.25
VCYT
+7.04%
2.71
INMB
-2.52%
18.95
URGN
+5.28%

FAQ

What Stock Exchange Does Kodiak Sciences Trade On?

Kodiak Sciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Kodiak Sciences?

The stock symbol for Kodiak Sciences is "KOD."

What Is the Kodiak Sciences Market Cap?

As of today, Kodiak Sciences market cap is 465.25M.

What Is Kodiak Sciences's Earnings Per Share (TTM)?

The Kodiak Sciences EPS (TTM) is -3.62.

When Is the Next Kodiak Sciences Earnings Date?

Kodiak Sciences will release its next earnings report on 17 Aug 2025.

From a Technical Analysis Perspective, Is KOD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Kodiak Sciences Stock Split?

Kodiak Sciences has split 0 times.

How Many Employees Does Kodiak Sciences Have?

Kodiak Sciences has 113 employees.

What is the current trading status of Kodiak Sciences (KOD)?

As of 26 Jul 2025, Kodiak Sciences (KOD) is trading at a price of 8.84, with a previous close of 8.25. The stock has fluctuated within a day range of 7.96 to 8.86, while its 52-week range spans from 1.92 to 11.60.

What Is Kodiak Sciences (KOD) Price Target According to Analysts?

The average 12-month price target for Kodiak Sciences is USD7.25, with a high estimate of USD20 and a low estimate of USD2. 2 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an -17.99% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.